**Name of journal: *World Journal of Stem Cells***

**ESPS Manuscript NO: 6652**

**Columns: TOPIC HIGHLIGHT**

WJSC 6th Anniversary Special Issues (2): Mesenchymal stem cells

**Adipose mesenchymal stem cells in the field of bone tissue engineering**

Romagnoli C *et al.* Adipose-derived stem cells in bone regeneration

Cecilia Romagnoli, Maria Luisa Brandi

**Cecilia Romagnoli, Maria Luisa Brandi,** Metabolic Bone Diseases Branch, Department of Surgery and Translational Medicine, University of Florence, Florence 50139, Italy

**Author contributions:** Romagnoli C conceived and designed the paper, reviewed the literature and wrote the paper; Brandi ML revised and approved the final version of the paper.

**Supported by** the Regione Toscana-POR CRO FSE 2007-2013 and I.F.B. STRODER s.r.l.

**Correspondence to: Maria Luisa Brandi, MD, PhD,** Metabolic Bone Diseases Branch, Department of Surgery and Translational Medicine, University of Florence, Largo Palagi 1, Florence 50139, Italy. marialuisa.brandi@unifi.it

**Telephone:** +39-55-7946304 **Fax:** +39-55-7946303

**Received:** November 19, 2013 **Revised:** December 19, 2013

**Accepted: March 03, 2014**

**Published online:**

**Abstract**

Bone tissue engineering represents one of the most challenging emergent fields for scientists and clinicians. Current failures of autografts and allografts in many pathological conditions have prompted researchers to find new biomaterials able to promote bone repair or regeneration with specific characteristics of biocompatibility, biodegradability and osteoinductivity. Recent advancements for tissue regeneration in bone defects have occurred by following the diamond concept and combining the use of growth factors and mesenchymal stem cells (MSCs). In particular, a more abundant and easily accessible source of MSCs was recently discovered in adipose tissue. These adipose stem cells (ASCs) can be obtained in large quantities with little donor site morbidity or patient discomfort, in contrast to the invasive and painful isolation of bone marrow MSCs. The osteogenic potential of ASCs on scaffolds has been examined in cell cultures and animal models, with only a few cases reporting the use of ASCs for successful reconstruction or accelerated healing of defects of the skull and jaw in patients. Although these reports extend our limited knowledge concerning the use of ASCs for osseous tissue repair and regeneration, the lack of standardization in applied techniques makes the comparison between studies difficult. Additional clinical trials are needed to assess ASC therapy and address potential ethical and safety concerns, which must be resolved to permit application in regenerative medicine.

© 2014 Baishideng Publishing Group Co., Limited. All rights reserved.

**Key words:** Adipose-derived stem cells; Bone tissue engineering; Osteogenic differentiation; Scaffold; Regenerative medicine

**Core tip:** The complex and dynamic process of bone tissue engineering is a challenging field in regenerative medicine. Current research is focused on the optimization and facilitation of bone regeneration by combining growth factors and mesenchymal stem cells with the many types of materials that have been studied as scaffolds. This review presents an overview of ideal scaffold properties and discusses the application of adipose-derived stem cells in bone tissue engineering and translational medicine.

Romagnoli C, Brandi ML. Adipose mesenchymal stem cells in the field of bone tissue engineering.

**Available from:**

**DOI:**

**INTRODUCTION**

Recent progress in the field of bone tissue engineering has led to new and exciting research concerning regenerative medicine. This interdisciplinary field is focused on the development of biological substitutes that restore, maintain or improve tissue function by applying the principles of engineering and the life sciences[1]. The primary target of clinical therapeutic strategies is the regeneration of bone for skeletal reconstruction of large bone defects created by trauma, infection, tumor resection and skeletal abnormalities, or cases in which the regenerative process is compromised, including avascular necrosis, atrophic non-union and osteoporosis. Strategies that stimulate bone healing to reduce or treat complications are becoming more important, due to the increase in life expectancy and ageing of the world population.

Autologous grafts represent the “ideal graft bone substitutes” and are currently the gold standard therapeutic strategy as they combine all essential components to induce bone growth and regeneration, including osteogenic cells, osteoinductive growth factors and bone-supporting matrix. Autografts are non-immunogenic and histocompatible, as they are the patient’s own tissue. Although they reduce the likelihood of immunoreaction and transmission of infection[2], autografts are limited and commonly result in donor site morbidity as a result of the additional surgical harvesting procedures, and are accompanied by the risk of infection, hematoma and chronic pain, which can all lead to implant failure[3-7]. An alternative approach involves the use of allogenic bone grafts obtained from human cadavers or living donors, which bypasses the complications associated with harvesting and quantity of graft materials. However, allogenic grafts are limited by tissue matching, disease transmission, batch variability and an inability to survive and integrate following implantation[8-10].

The limited success of auto- and allografts in some clinical situations has stimulated the investigation of a wide variety of biomaterials to be used as scaffolds, and the development of promising clinical therapies[11]. Advantages to utilizing sophisticated bone scaffolds include the elimination of the risk for disease transmission, fewer surgical procedures, and reduced risk of infection or immunogenicity. Moreover, there is an abundant availability of synthetic or natural biomaterials that can be employed, including collagen, hydroxyapatite (HA), β-tricalcium phosphate (β-TCP), calcium phosphate cements and glass ceramics. The concept of bone substitution involves the replacement of bone structure to allow the migration, proliferation and differentiation of bone cells and to promote vascularisation, thus utilizing the body’s natural biological response to tissue damage in conjunction with engineering principles. Current models of *in vitro* bone formation are based on the idea that the same factors known to play a role during embryonic development can be used to induce cellular differentiation and function in the process of regeneration[12]. In order to engineer an environment supporting bone formation, combinations of biochemical and biophysical signals need to be presented to the cells in a three-dimensional setting in a way that allows interactions between the surrounding cells and the extracellular matrix. The complexity of signaling, with temporal and spatial gradients of molecular and physical factors affecting bone morphogenesis, presents significant challenges to engineering fully viable, functional bone. This “diamond concept” has allowed the scientific community to consider more complex interactions between scaffolds, cells and growth factors in order to induce tissue regeneration in bone defects[13]. This article presents a concise review regarding the main properties of scaffolds, the most recent progress in bone tissue engineering using human adipose-derived stem cells and current models used for bone regeneration.

**PROPERTIES OF ENGINEERED BONE SCAFFOLDS**

An ideal scaffold must address multiple physical and biological requirements in order to optimize bone regeneration. One of the most important stages of bone tissue engineering is the design and processing of a porous, biodegradable three-dimensional (3D) structure. This scaffold provides a structural and logistical template for developing tissue, which can markedly affect cell behavior. The properties of scaffolds that are important for bone formation include the size, distribution and shape of the pores, the surface roughness, the presence of cell attachment sites and the biomechanics of both the material and the scaffold structures[14-17]. The most suitable scaffolds for bone formation are those made of osteoconductive materials, such as bone proteins and HA, with mechanical properties similar to those of load-bearing native bone that stimulate osteogenesis and have large and interconnected pores to facilitate cell infiltration and matrix deposition, and rough inner surfaces to promote cell attachment. Additionally, scaffolds should be anisotropic structures that can be fashioned into anatomically correct shapes that also have the capacity for vascularization. Scaffolds should also incorporate and control the delivery of bioactive molecules, such as growth factors or drugs that regulate cellular function, accelerating healing and preventing pathology[18,19]. Furthermore, as scaffolds will be replaced over time by new formed bone, they should be comprised of resorbable materials, or materials that degrade in an enzymatic or hydrolytic way, such as polymers, or can be dissolved by cells such as osteoclasts[20,21].

The majority of studies are currently focused on the development of 3D structures that mimic the anatomical and biochemical organization of cells and native matrix in order to achieve suitable mechanical properties for bone tissue[22]. Numerous materials have been shown to support *in vitro* bone formation by human cells, including bioceramics like HA, β-TCP, bio-glasses and biodegradable polymers[23,24], and natural or synthetic collagen, fibrin, chitosan or polyesters[25,26]. Scaffolds containing composites of these materials provide an optimized and convenient alternative as they combine the advantages of both bioactive ceramics and biodegradable polymers[27-31].

**OSTEOINDUCTIVE BIOMOLECULES**

One of the most challenging tasks for the development of bone graft substitutes is to produce scaffolds with osteoinductive properties, which can involve the application of biologically active molecules. Growth factors that naturally occur within a healthy bone matrix or are expressed during fracture healing can be used to direct the development of structures, vascularization and differentiation of bone cells[19]. Growth factors, such as cytokines, are endogenous proteins that act on a wide variety of cells and direct their actions by binding to and activating cell-surface receptors. As developmental bone formation is an orchestrated cellular process tightly controlled by actions of growth factors, their use in engineered scaffolds is an obvious strategy when the bone integrity is compromised and bone tissue needs to be repaired[32,33]. This strategy aims to enhance the local presence of bone-depositing osteoblasts, either by attracting the cells to the repair site or by inducing the proliferation of local undifferentiated precursor cells, followed by the transformation of precursor cells into an osteoblastic phenotype[34].

The introduction of specific biomolecules has been shown in animal models to enhance the union of non-union type (a fracture that does not heal by itself after several months) bone fractures[32]. Many growth factors that have been used in bone repair with some degree of success include mitogens such as platelet-derived growth factors, metabolic regulators such as insulin-like growth factors, angiogenic proteins such as basic fibroblast growth factors, and morphogens such as bone morphogenetic proteins (BMPs)[35-39]. BMPs, which are members of the transforming growth factor beta (TGF-β) superfamily, have been the most extensively studied, as they are potent osteoinductive factors that induce the mitogenesis and differentiation of mesenchymal stem cells and other osteoprogenitors[35,11]. They are a very promising candidate for the treatment of bone diseases and defects, as a number of experimental and clinical trials demonstrate their safety and efficacy[40-42]. However, the clinical application of BMPs is currently limited to the use of BMP-2 for open tibial fractures and spinal fusion, and BMP-7 (OP-1) for non-unions with limited indication for spinal fusion[43,44], which were approved by the U.S. Food and Drug Administration in 2004. The clinical and scientific utility of bone tissue engineering largely depends on the ability to create scaffolds with specific characteristics that predictably direct cells to differentiate into the right phenotypes in a spatially and temporally defined pattern guided by molecular and physical factors.

**HUMAN ADIPOSE-DERIVED MESENCHYMAL STEM CELLS**

The combination of engineered scaffolds with recent developments in the emerging field of stem cell science may allow the use of stem cells to repair tissue damage and, eventually, to replace organs. Multipotent stem cells (MSCs) are non-hematopoietic cells of mesodermal derivation that are present in a number of postnatal organs and connective tissues. The stroma of bone marrow contains bone marrow mesenchymal stem cells (BMSCs) capable of differentiating into osteogenic, chondrogenic, adipogenic and endothelial lineages[45-48], and thus is the most well studied source of MSCs for bone regeneration. Bone marrow transplantation is also being used clinically in combination with osteoconductive materials to augment bone healing[9].

In the last few years, MSCs have been isolated from other tissue sources including trabecular bone[49], synovium[50], umbilical cord[51], periodontal ligament[52] and other dental tissues[53], skeletal muscle, cord blood and skin[54-56]. Although the stem cell populations derived from these sources are valuable, common problems include limited amounts of available tissues and low numbers of harvested cells, which necessitate at least some degree of *ex vivo* expansion or further manipulation before preclinical or clinical use. In contrast, a promising population of MSCs has been identified within adipose tissue, termed adipose-derived stem/stromal cells (ASCs) by the regenerative medicine community during the Second Annual International Fat Applied Technology Society Meeting in 2004. Human adipose tissue is ubiquitous and can easily be obtained in large quantities with little donor site morbidity or patient discomfort[45], in contrast to the invasive and painful procedure for isolating BMSCs. Moreover, stem cell yields are greater from adipose tissue than from other stem cells reservoirs, a significant factor for use in regenerative medicine. As many 1 × 107 ASCs can routinely be isolated from 300 ml of lipoaspirate, with greater than 95% purity. ASCs comprise 2% of nucleated cells in processed lipoaspirate, with a yield of 5000 fibroblast colony-forming units (CFU-F) per gram of adipose tissue, compared with estimates of about 100-1000 CFU-F per ml of bone marrow[57,58]. In general, cell isolation protocols include density gradient centrifugation of the collagenase-digested tissue (lipoaspirate or minced adipose tissue)[57-61], followed by the seeding of the pelleted stromal vascular fraction (SVF) on monolayer culture plastics. The adherent cell population can then be expanded and used in a variety of assays.

Although the study of human ASCs (hASCs) is emerging, the standardization of isolation and culture procedures could improve quality control and facilitate comparisons between different studies. There are discrepancies in the results of studies from different laboratories due to differences in the methods and quality of hASC isolation, which can affect the composition of the initial cell culture, as well as in the procedures used to culture the cells. Cell culture basal medium, generally containing 10% fetal bovine serum, is often supplemented with epidermal growth factor, fibroblast growth factor-2 and/or TGF-β[58,62,63]. In addition, some protocols may recommend differing initial cell seeding densities, though evidence suggests that low seeding densities and subconfluent passaging are recommended[64,65]. Other variables that may affect the composition of the initial isolated cell culture cannot be standardized, such as donor age, gender, body mass index, ethnicity and medical history[66]. It is therefore important to standardize hASC isolation and culturing methods to maximize the reliability and reproducibility of results from different laboratories.

**COMPOSITION AND CHARACTERIZATION OF CULTURED hASCs**

The SVF that is obtained from processed adipose tissue contains a highly heterogeneous cell population, including non-adherent cell populations. A complete characterization of SVF cell populations was done by Yoshimura *et al*[64] in which they identified endothelial cells, pericytes, blood-derived cells, fibroblasts, vascular smooth muscle cells and preadipocytes, in addition to the potential hASCs. Although the adherence of hASCs allows for their selection from the SVF during subsequent tissue culture passages, other cell types, such as fibroblasts, can also adhere to the culture plastic. Thus, other cell types, or subpopulations, may compromise the proliferation and/or differentiation potential of hASCs.

To reduce the heterogeneity of cultured ASCs, a washing procedure in the beginning of the cell culture can be used, as various cell types adhere to the plastic at different time points[66]. Additionally, flow cytometric sorting or immunomagnetic separation with specific cell surface markers can be used to isolate and purify specific subpopulations of hASCs. However, there is considerable heterogeneity in commonly analyzed hASC surface markers, which can be modified by the culturing procedure. The cell phenotype can also be influenced by differences in the cell purification procedure and by the number of passages[66-70]. Mitchell *et al*[59] identified hematopoietic lineage cells from the SVF using flow cytometry based on their expression of CD1, CD14, CD45 and other markers, which were lost with progressive passages. The loss of these markers indicates that they do not represent the adherent population. Moreover, SVF cells exhibit low levels of classic stromal cell markers (CD13, CD29, CD44, CD73, CD90, CD105, CD166) in the earliest stages of isolation, and assume a more homogeneous profile with consistently high levels of stromal markers after four to five passages, a temporal expression pattern that resembles what has been reported in human BMSCs[54]. Work from Rada *et al*[71]demonstrated the complexity of hASC populations by showing that they are composed of several subpopulations that express different levels of hASC markers and exhibit distinctive differentiation potentials. In their study, hASC subpopulations were isolated using immunomagnetic beads specific for CD29, CD44, CD49, CD73, CD90, CD105, p75 and STRO-1, and cultured with specific chondrogenic or osteogenic media in order to evaluate their differentiation potential into these lineages. Among all the hASC subpopulations isolated, STRO-1-containing populations had the highest osteogenic potential, with the highest chondrogenic differentiation potential in populations expressing CD29 and CD105. These data clearly demonstrate that SVF from adipose tissue is comprised of several stem cell subpopulations that exhibit *in vitro* chondrogenic and osteogenic differentiation profiles. Therefore, these subpopulations should be studied in order to select those most suitable for application in bone and cartilage regenerative medicine.

**APPLICATION OF hASCs AND SCAFFOLDS FOR BONE TISSUE ENGINEERING**

Since the discovery of hASC osteogenic differentiation, substantial progress has been made toward the use of these cells as an optimal source for bone regeneration. Although initial applications involved the direct administration of stem cells into the target fracture site, current paradigms using scaffolds loaded with stem cells are preferred as they provide support for cell colonization, migration, growth and differentiation[72]. Combined with the support of a scaffold, the directed osteogenesis of hASCs confirms that adipose tissue is a promising autologous source of osteoblastic cells for bone regeneration. Utilization of hASCs in scaffolds for bone tissue engineering has been heralded as the alternative strategy of the 21st century to replace or restore the function of traumatized, damaged or lost bone.

In the last ten years, several cell characterization studies have extensively described the differentiation potential and function of hASCs *in vitro*[58,62,67,69]. Many types of materials have been used to confirm these positive hASC characteristics, which have become available for scaffold-assisted bone regeneration in a variety of tissue engineering strategies. The importance of the scaffold in hASC osteogenesis has been demonstrated in a number of studies that recommend the use of different materials, including ceramics[73], titan alloys[74,75], natural and synthetic polymers[76,77], and natural or semi-synthetic grafts[78,79], with variable porosity, roughness, and methods of fabrication for future regenerative applications. A clear trend has emerged toward the use of composite scaffolds due to their superior properties and structures[80-82] derived from the combination of two or more materials[83-87].

The study of hASCs for bone regeneration has largely involved the insertion of biomaterials in rat and nude mouse models[88-92]. Furthermore, a femoral defect in nude rats is available and calvarial defect models have been described for other species, to demonstrate the application and optimization of hASCs in regenerative medicine[93-97]. However, relatively few reports are available concerning the utilization of hASCs for human bone tissue regeneration (Table 1). The first compelling evidence supporting the clinical application of an hASC scaffold to promote fracture healing was reported by Lendeckel *et al*[98] in 2004. In this work, a combination of autologous hASCs obtained from the gluteal region and bone grafts from the dorsal iliac crest was used for the treatment of a multi-fragment calvarial fracture in a 7-year-old girl. An autologous fibrin glue was applied using a spray adapter to keep the cells in place, and postoperative healing was uneventful after three months. In 2009, Mesimäki *et al*[99] described a novel method to reconstruct a major maxillary defect in an adult patient using autologous hASCs that were produced in clean room facilities free of animal-derived reagents, combined with recombinant human BMP-2 and β-TCP granules. The patient’s healing was also clinically uneventful in this case, thus paving the way for extensive clinical trials using ASCs in custom-made implants for the reconstruction of bone defects. Moreover, the use of autologous cells, handled and prepared without animal-derived materials with good manufacturing practices in standard clean rooms, demonstrates that these cells can be considered safe for applications in tissue regeneration, according to the clinical cell therapy safety standards of the European Union.

Defects of the skull and jaws have been successfully reconstructed or their healing has been accelerated by the use of hASCs[98-102], extending our limited knowledge regarding the potential use of hASCs for osseous tissue repair and regeneration. Work published in 2012 by Sándor demonstrates the synergistic effect of hASCs, resorbable scaffolds (β-TCP and bioactive glass) and growth factors (BMP-2), in the treatment of 23 patients with craniofacial osseous defects[103]. He has established the utility of hASCs in combination with biomaterials in 85% of the cases followed after bone reconstruction, though the long-term success of this procedure needs to be verified using a large sample.

**CONCLUSION AND FUTURE PERSPECTIVES**

The emerging application of hASCs on engineered scaffolds for bone tissue regeneration represents the most exciting challenge for the scientific community in future translational medicine. The ability to obtain a large quantity of MSCs from easily accessible adipose tissue, combined with the growing research on new biomaterials incorporating bioactive molecules such as drugs and growth factors, opens the way to new therapeutic applications. Although clinical trials have demonstrated the use of hASCs for the reconstruction of craniofacial defects in humans, there are many aspects that need to be examined and resolved. Further investigations are needed to standardize procedures for harvesting, isolating, cultivating and preparing hASCs for clinical applications. The differences in currently applied techniques make comparisons across studies difficult. Moreover, the lack of guidelines for the proper utilization of different bone scaffold materials may provoke safety concerns, impeding clinical trials and the translation of scaffold technologies to the clinical environment. Prospective randomized clinical trials are needed to identify clear indications for and to demonstrate clinical outcomes of the hASC therapies. Ethical and safety concerns must be resolved to prevent human testing as the first stage in novel scaffold development.

**REFERENCES**

1 **Rosa AL**, de Oliveira PT, Beloti MM. Macroporous scaffolds associated with cells to construct a hybrid biomaterial for bone tissue engineering. *Expert Rev Med Devices* 2008; **5**: 719-728 [PMID: 19025348 DOI: 10.1586/17434440.5.6.719]

2 **Bauer TW**, Muschler GF. Bone graft materials. An overview of the basic science. *Clin Orthop Relat Res* 2000; **(371)**: 10-27 [PMID: 10693546 DOI: 10.1097/00003086-200002000-00003]

3 **Arrington ED**, Smith WJ, Chambers HG, Bucknell AL, Davino NA. Complications of iliac crest bone graft harvesting. *Clin Orthop Relat Res* 1996; **(329)**: 300-309 [PMID: 8769465 DOI: 10.1097/00003086-199608000-00037]

4 **Banwart JC**, Asher MA, Hassanein RS. Iliac crest bone graft harvest donor site morbidity. A statistical evaluation. *Spine* (Phila Pa 1976) 1995; **20**: 1055-1060 [PMID: 7631235 DOI: 10.1097/00007632-199505000-00012]

5 **Ahlmann E**, Patzakis M, Roidis N, Shepherd L, Holtom P. Comparison of anterior and posterior iliac crest bone grafts in terms of harvest-site morbidity and functional outcomes. *J Bone Joint Surg Am* 2002; **84-A**: 716-720 [PMID: 12004011]

6 **St John TA**, Vaccaro AR, Sah AP, Schaefer M, Berta SC, Albert T, Hilibrand A. Physical and monetary costs associated with autogenous bone graft harvesting. *Am J Orthop* (Belle Mead NJ) 2003; **32**: 18-23 [PMID: 12580346]

7 **Younger EM**, Chapman MW. Morbidity at bone graft donor sites. *J Orthop Trauma* 1989; **3**: 192-195 [PMID: 2809818 DOI: 10.1097/00005131-198909000-00002]

8 **Giannoudis PV**, Dinopoulos H, Tsiridis E. Bone substitutes: an update. *Injury* 2005; **36** Suppl 3: S20-S27 [PMID: 16188545 DOI: 10.1016/j.injury.2005.07.029]

9 **Finkemeier CG**. Bone-grafting and bone-graft substitutes. *J Bone Joint Surg Am* 2002; **84-A**: 454-464 [PMID: 11886919]

10 **Marolt D**, Knezevic M, Novakovic GV. Bone tissue engineering with human stem cells. *Stem Cell Res Ther* 2010; **1**: 10 [PMID: 20637059 DOI: 10.1186/scrt10]

11 **Dimitriou R**, Jones E, McGonagle D, Giannoudis PV. Bone regeneration: current concepts and future directions. *BMC Med* 2011; **9**: 66 [PMID: 21627784 DOI: 10.1186/1741-7015-9-66]

12 **Vunjak-Novakovic G**, Meinel L, Altman G, Kaplan D. Bioreactor cultivation of osteochondral grafts. *Orthod Craniofac Res* 2005; **8**: 209-218 [PMID: 16022723 DOI: 10.1111/j.1601-6343.2005.00334.x]

13 **Giannoudis PV**, Einhorn TA, Schmidmaier G, Marsh D. The diamond concept--open questions. *Injury* 2008; **39** Suppl 2: S5-S8 [PMID: 18804574 DOI: 10.1016/S0020-1383(08)70010-X]

14 **Hofmann S**, Hagenmüller H, Koch AM, Müller R, Vunjak-Novakovic G, Kaplan DL, Merkle HP, Meinel L. Control of in vitro tissue-engineered bone-like structures using human mesenchymal stem cells and porous silk scaffolds. *Biomaterials* 2007; **28**: 1152-1162 [PMID: 17092555 DOI: 10.1016/j.biomaterials.2006.10.019]

15 **Dalby MJ**, Gadegaard N, Tare R, Andar A, Riehle MO, Herzyk P, Wilkinson CD, Oreffo RO. The control of human mesenchymal cell differentiation using nanoscale symmetry and disorder. *Nat Mater* 2007; **6**: 997-1003 [PMID: 17891143 DOI: 10.1038/nmat2013]

16 **Comisar WA**, Kazmers NH, Mooney DJ, Linderman JJ. Engineering RGD nanopatterned hydrogels to control preosteoblast behavior: a combined computational and experimental approach. *Biomaterials* 2007; **28**: 4409-4417 [PMID: 17619056 DOI: 10.1016/j.biomaterials.2007.06.018]

17 **Engler AJ**, Sen S, Sweeney HL, Discher DE. Matrix elasticity directs stem cell lineage specification. *Cell* 2006; **126**: 677-689 [PMID: 16923388 DOI: 10.1016/j.cell.2006.06.044]

18 **Karageorgiou V**, Tomkins M, Fajardo R, Meinel L, Snyder B, Wade K, Chen J, Vunjak-Novakovic G, Kaplan DL. Porous silk fibroin 3-D scaffolds for delivery of bone morphogenetic protein-2 in vitro and in vivo. *J Biomed Mater Res A* 2006; **78**: 324-334 [PMID: 16637042 DOI: 10.1002/jbm.a.30728]

19 **Janicki P**, Schmidmaier G. What should be the characteristics of the ideal bone graft substitute? Combining scaffolds with growth factors and/or stem cells. *Injury* 2011; **42** Suppl 2: S77-S81 [PMID: 21724186 DOI: 10.1016/j.injury.2011.06.014]

20 **Schmidt-Rohlfing B**, Tzioupis C, Menzel CL, Pape HC. [Tissue engineering of bone tissue. Principles and clinical applications]. *Unfallchirurg* 2009; **112**: 785-94; quiz 795 [PMID: 19756458 DOI: 10.1007/s00113-009-1695-x]

21 **Liao SS**, Cui FZ. In vitro and in vivo degradation of mineralized collagen-based composite scaffold: nanohydroxyapatite/collagen/poly(L-lactide). *Tissue Eng* 2004; **10**: 73-80 [PMID: 15009932 DOI: 10.1089/107632704322791718]

22 **Zhang G**. Biomimicry in biomedical research. *Organogenesis* 2012; **8**: 101-102 [PMID: 23275257 DOI: 10.4161/org.23395]

23 **Mygind T**, Stiehler M, Baatrup A, Li H, Zou X, Flyvbjerg A, Kassem M, Bünger C. Mesenchymal stem cell ingrowth and differentiation on coralline hydroxyapatite scaffolds. *Biomaterials* 2007; **28**: 1036-1047 [PMID: 17081601 DOI: 10.1016/j.biomaterials.2006.10.003]

24 **Boukhechba F**, Balaguer T, Michiels JF, Ackermann K, Quincey D, Bouler JM, Pyerin W, Carle GF, Rochet N. Human primary osteocyte differentiation in a 3D culture system. *J Bone Miner Res* 2009; **24**: 1927-1935 [PMID: 19419324 DOI: 10.1359/jbmr.090517]

25 **Turhani D**, Watzinger E, Weissenböck M, Yerit K, Cvikl B, Thurnher D, Ewers R. Three-dimensional composites manufactured with human mesenchymal cambial layer precursor cells as an alternative for sinus floor augmentation: an in vitro study. *Clin Oral Implants Res* 2005; **16**: 417-424 [PMID: 16117765 DOI: 10.1111/j.1600-0501.2005.01144.x]

26 **Meinel L**, Karageorgiou V, Fajardo R, Snyder B, Shinde-Patil V, Zichner L, Kaplan D, Langer R, Vunjak-Novakovic G. Bone tissue engineering using human mesenchymal stem cells: effects of scaffold material and medium flow. *Ann Biomed Eng* 2004; **32**: 112-122 [PMID: 14964727 DOI: 10.1023/B: ABME.0000007796.48329.b4]

27 **Chesnutt BM**, Yuan Y, Buddington K, Haggard WO, Bumgardner JD. Composite chitosan/nano-hydroxyapatite scaffolds induce osteocalcin production by osteoblasts in vitro and support bone formation in vivo. *Tissue Eng Part A* 2009; **15**: 2571-2579 [PMID: 19309240 DOI: 10.1089/ten.tea.2008.0054]

28 **Wahl DA**, Czernuszka JT. Collagen-hydroxyapatite composites for hard tissue repair. *Eur Cell Mater* 2006; **11**: 43-56 [PMID: 16568401]

29 **Li XM**, Feng QL, Cui FZ. In vitro degradation of porous nano-hydroxyapatite/collagen/PLLA scaffold reinforced by chitin fibres. *Mater Sci Eng C* 2006; **26**: 716-720

30 **Liao SS**, Cui FZ, Zhu Y. Osteoblasts adherence and migration through three dimensional porous mineralized collagen based composite: nHAC/PLA. *J Bioact Comp Polym* 2004; **19**: 117-130 [DOI: 10.1177/0883911504042643]

31 **Zhang P**, Wu H, Wu H, Lù Z, Deng C, Hong Z, Jing X, Chen X. RGD-conjugated copolymer incorporated into composite of poly(lactide-co-glycotide) and poly(L-lactide)-grafted nanohydroxyapatite for bone tissue engineering. *Biomacromolecules* 2011; **12**: 2667-2680 [PMID: 21604718 DOI: 10.1021/bm2004725]

32 **Li J**, Hong J, Zheng Q, Guo X, Lan S, Cui F, Pan H, Zou Z, Chen C. Repair of rat cranial bone defects with nHAC/PLLA and BMP-2-related peptide or rhBMP-2. *J Orthop Res* 2011; **29**: 1745-1752 [PMID: 21500252 DOI: 10.1002/jor.21439]

33 **Varkey M**, Gittens SA, Uludag H. Growth factor delivery for bone tissue repair: an update. *Expert Opin Drug Deliv* 2004; **1**: 19-36 [PMID: 16296718 DOI: 10.1517/17425247.1.1.19]

34 **Gittens SA**, Uludag H. Growth factor delivery for bone tissue engineering. *J Drug Target* 2001; **9**: 407-429 [PMID: 11822814 DOI: 10.3109/10611860108998776]

35 **Lieberman JR**, Daluiski A, Einhorn TA. The role of growth factors in the repair of bone. Biology and clinical applications. *J Bone Joint Surg Am* 2002; **84-A**: 1032-1044 [PMID: 12063342]

36 **Solheim E**. Growth factors in bone. *Int Orthop* 1998; **22**: 410-416 [PMID: 10093814 DOI: 10.1007/s002640050290]

37 **Luginbuehl V**, Wenk E, Koch A, Gander B, Merkle HP, Meinel L. Insulin-like growth factor I-releasing alginate-tricalciumphosphate composites for bone regeneration. *Pharm Res* 2005; **22**: 940-950 [PMID: 15948038 DOI: 10.1007/s11095-005-4589-9]

38 **Hernández A**, Reyes R, Sánchez E, Rodríguez-Évora M, Delgado A, Evora C. In vivo osteogenic response to different ratios of BMP-2 and VEGF released from a biodegradable porous system. *J Biomed Mater Res A* 2012; **100**: 2382-2391 [PMID: 22528545 DOI: 10.1002/jbm.a.34183]

39 **Wei G**, Jin Q, Giannobile WV, Ma PX. Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. *J Control Release* 2006; **112**: 103-110 [PMID: 16516328 DOI: 10.1016/j.jconrel.2006.01.011]

40 **Rauch F**, Lauzier D, Croteau S, Travers R, Glorieux FH, Hamdy R. Temporal and spatial expression of bone morphogenetic protein-2, -4, and -7 during distraction osteogenesis in rabbits. *Bone* 2000; **27**: 453-459 [PMID: 10962359 DOI: 10.1016/S8756-3282(00)00337-9]

41 **Canalis E**, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. *Endocr Rev* 2003; **24**: 218-235 [PMID: 12700180 DOI: 10.1210/er.2002-0023]

42 **Wan M**, Cao X. BMP signaling in skeletal development. *Biochem Biophys Res Commun* 2005; **328**: 651-657 [PMID: 15694398 DOI: 10.1016/j.bbrc.2004.11.067]

43 **Friedlaender GE**, Perry CR, Cole JD, Cook SD, Cierny G, Muschler GF, Zych GA, Calhoun JH, LaForte AJ, Yin S. Osteogenic protein-1 (bone morphogenetic protein-7) in the treatment of tibial nonunions. *J Bone Joint Surg Am* 2001; **83-A** Suppl 1: S151-S158 [PMID: 11314793]

44 **Govender S**, Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Börner MG, Chiron P, Choong P, Cinats J, Courtenay B, Feibel R, Geulette B, Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl RL, Lindeque B, Lob G, Mathevon H, McCoy G, Marsh D, Miller R, Munting E, Oevre S, Nordsletten L, Patel A, Pohl A, Rennie W, Reynders P, Rommens PM, Rondia J, Rossouw WC, Daneel PJ, Ruff S, Rüter A, Santavirta S, Schildhauer TA, Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne RB, Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T; BMP-2 Evaluation in Surgery for Tibial Trauma (BESTT) Study group. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. *J Bone Joint Surg Am* 2002; **84-A**: 2123-2134 [PMID: 12473698]

45 **Zuk PA**, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, Benhaim P, Lorenz HP, Hedrick MH. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng* 2001; **7**: 211-228 [PMID: 11304456 DOI: 10.1089/107632701300062859]

46 **Sudo K**, Kanno M, Miharada K, Ogawa S, Hiroyama T, Saijo K, Nakamura Y. Mesenchymal progenitors able to differentiate into osteogenic, chondrogenic, and/or adipogenic cells in vitro are present in most primary fibroblast-like cell populations. *Stem Cells* 2007; **25**: 1610-1617 [PMID: 17395773 DOI: 10.1634/stemcells.2006-0504]

47 **Friedenstein AJ**, Chailakhyan RK, Gerasimov UV. Bone marrow osteogenic stem cells: in vitro cultivation and transplantation in diffusion chambers. *Cell Tissue Kinet* 1987; **20**: 263-272 [PMID: 3690622 DOI: 10.1111/j.1365-2184.1987.tb01309.x]

48 **Gimble JM**, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. *Circ Res* 2007; **100**: 1249-1260 [PMID: 17495232 DOI: 10.1161/01.RES.0000265074.83288.09]

49 **Song L**, Young NJ, Webb NE, Tuan RS. Origin and characterization of multipotential mesenchymal stem cells derived from adult human trabecular bone. *Stem Cells Dev* 2005; **14**: 712-721 [PMID: 16433626 DOI: 10.1089/scd.2005.14.712]

50 **De Bari C**, Dell'Accio F, Tylzanowski P, Luyten FP. Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheum* 2001; **44**: 1928-1942 [PMID: 11508446 DOI: 10.1002/1529-0131(200108)44: 8<1928::AID-ART331>3.0.CO;2-P]

51 **Baksh D**, Yao R, Tuan RS. Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow. *Stem Cells* 2007; **25**: 1384-1392 [PMID: 17332507 DOI: 10.1634/stemcells.2006-0709]

52 **Seo BM**, Miura M, Gronthos S, Bartold PM, Batouli S, Brahim J, Young M, Robey PG, Wang CY, Shi S. Investigation of multipotent postnatal stem cells from human periodontal ligament. *Lancet* 2004; **364**: 149-155 [PMID: 15246727 DOI: 10.1016/S0140-6736(04)16627-0]

53 **Miura M**, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S. SHED: stem cells from human exfoliated deciduous teeth. *Proc Natl Acad Sci USA* 2003; **100**: 5807-5812 [PMID: 12716973 DOI: 10.1073/pnas.0937635100]

54 **Pittenger MF**, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999; **284**: 143-147 [PMID: 10102814 DOI: 10.1126/science.284.5411.143]

55 **Caplan AI**. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. *J Cell Physiol* 2007; **213**: 341-347 [PMID: 17620285 DOI: 10.1002/jcp.21200]

56 **Choi YS**, Noh SE, Lim SM, Lee CW, Kim CS, Im MW, Lee MH, Kim DI. Multipotency and growth characteristic of periosteum-derived progenitor cells for chondrogenic, osteogenic, and adipogenic differentiation. *Biotechnol Lett* 2008; **30**: 593-601 [PMID: 17985079 DOI: 10.1007/s10529-007-9584-2]

57 **Boquest AC**, Shahdadfar A, Brinchmann JE, Collas P. Isolation of stromal stem cells from human adipose tissue. *Methods Mol Biol* 2006; **325**: 35-46 [PMID: 16761717 DOI: 10.1385/1-59745-005-7: 35]

58 **Strem BM**, Hicok KC, Zhu M, Wulur I, Alfonso Z, Schreiber RE, Fraser JK, Hedrick MH. Multipotential differentiation of adipose tissue-derived stem cells. *Keio J Med* 2005; **54**: 132-141 [PMID: 16237275 DOI: 10.2302/kjm.54.132]

59 **Mitchell JB**, McIntosh K, Zvonic S, Garrett S, Floyd ZE, Kloster A, Di Halvorsen Y, Storms RW, Goh B, Kilroy G, Wu X, Gimble JM. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. *Stem Cells* 2006; **24**: 376-385 [PMID: 16322640 DOI: 10.1634/stemcells.2005-0234]

60 **Rodbell M**. Metabolism of isolated fat cells. II. The similar effects of phospholipase C (Clostridium perfringens alpha toxin) and of insulin on glucose and amino acid metabolism. *J Biol Chem* 1966; **241**: 130-139 [PMID: 4379054 DOI: 10.1002/cphy.cp050147]

61 **Aust L**, Devlin B, Foster SJ, Halvorsen YD, Hicok K, du Laney T, Sen A, Willingmyre GD, Gimble JM. Yield of human adipose-derived adult stem cells from liposuction aspirates. *Cytotherapy* 2004; **6**: 7-14 [PMID: 14985162 DOI: 10.1080/14653240310004539]

62 **Sterodimas A**, de Faria J, Nicaretta B, Pitanguy I. Tissue engineering with adipose-derived stem cells (ADSCs): current and future applications. *J Plast Reconstr Aesthet Surg* 2010; **63**: 1886-1892 [PMID: 19969517 DOI: 10.1016/j.bjps.2009.10.028]

63 **Varma MJ**, Breuls RG, Schouten TE, Jurgens WJ, Bontkes HJ, Schuurhuis GJ, van Ham SM, van Milligen FJ. Phenotypical and functional characterization of freshly isolated adipose tissue-derived stem cells. *Stem Cells Dev* 2007; **16**: 91-104 [PMID: 17348807 DOI: 10.1089/scd.2006.0026]

64 **Yoshimura K**, Shigeura T, Matsumoto D, Sato T, Takaki Y, Aiba-Kojima E, Sato K, Inoue K, Nagase T, Koshima I, Gonda K. Characterization of freshly isolated and cultured cells derived from the fatty and fluid portions of liposuction aspirates. *J Cell Physiol* 2006; **208**: 64-76 [PMID: 16557516 DOI: 10.1002/jcp.20636]

65 **Kingham PJ**, Kalbermatten DF, Mahay D, Armstrong SJ, Wiberg M, Terenghi G. Adipose-derived stem cells differentiate into a Schwann cell phenotype and promote neurite outgrowth in vitro. *Exp Neurol* 2007; **207**: 267-274 [PMID: 17761164 DOI: 10.1016/j.expneurol.2007.06.029]

66 **Baer PC**, Geiger H. Adipose-derived mesenchymal stromal/stem cells: tissue localization, characterization, and heterogeneity. *Stem Cells Int* 2012; **2012**: 812693 [PMID: 22577397 DOI: 10.1155/2012/812693]

67 **Locke M**, Windsor J, Dunbar PR. Human adipose-derived stem cells: isolation, characterization and applications in surgery. *ANZ J Surg* 2009; **79**: 235-244 [PMID: 19432707 DOI: 10.1111/j.1445-2197.2009.04852.x]

68 **Gronthos S**, Franklin DM, Leddy HA, Robey PG, Storms RW, Gimble JM. Surface protein characterization of human adipose tissue-derived stromal cells. *J Cell Physiol* 2001; **189**: 54-63 [PMID: 11573204 DOI: 10.1002/jcp.1138]

69 **Zuk PA**, Zhu M, Ashjian P, De Ugarte DA, Huang JI, Mizuno H, Alfonso ZC, Fraser JK, Benhaim P, Hedrick MH. Human adipose tissue is a source of multipotent stem cells. *Mol Biol Cell* 2002; **13**: 4279-4295 [PMID: 12475952 DOI: 10.1091/mbc.E02-02-0105]

70 **Boquest AC**, Shahdadfar A, Frønsdal K, Sigurjonsson O, Tunheim SH, Collas P, Brinchmann JE. Isolation and transcription profiling of purified uncultured human stromal stem cells: alteration of gene expression after in vitro cell culture. *Mol Biol Cell* 2005; **16**: 1131-1141 [PMID: 15635089 DOI: 10.1091/mbc.E04-10-0949]

71 **Rada T**, Reis RL, Gomes ME. Distinct stem cells subpopulations isolated from human adipose tissue exhibit different chondrogenic and osteogenic differentiation potential. *Stem Cell Rev* 2011; **7**: 64-76 [PMID: 20396979 DOI: 10.1007/s12015-010-9147-0]

72 **Lawrence BJ**, Madihally SV. Cell colonization in degradable 3D porous matrices. *Cell Adh Migr* 2008; **2**: 9-16 [PMID: 19262124 DOI: 10.4161/cam.2.1.5884]

73 **Li X**, Liu H, Niu X, Fan Y, Feng Q, Cui FZ, Watari F. Osteogenic differentiation of human adipose-derived stem cells induced by osteoinductive calcium phosphate ceramics. *J Biomed Mater Res B Appl Biomater* 2011; **97**: 10-19 [PMID: 21290570 DOI: 10.1002/jbm.b.31773]

74 **Tognarini I**, Sorace S, Zonefrati R, Galli G, Gozzini A, Carbonell Sala S, Thyrion GD, Carossino AM, Tanini A, Mavilia C, Azzari C, Sbaiz F, Facchini A, Capanna R, Brandi ML. In vitro differentiation of human mesenchymal stem cells on Ti6Al4V surfaces. *Biomaterials* 2008; **29**: 809-824 [PMID: 18022689 DOI: 10.1016/j.biomaterials.2007.10.043]

75 **Gastaldi G**, Asti A, Scaffino MF, Visai L, Saino E, Cometa AM, Benazzo F. Human adipose-derived stem cells (hASCs) proliferate and differentiate in osteoblast-like cells on trabecular titanium scaffolds. *J Biomed Mater Res A* 2010; **94**: 790-799 [PMID: 20336739 DOI: 10.1002/jbm.a.32721]

76 **Nardone V**, Fabbri S, Marini F, Zonefrati R, Galli G, Carossino A, Tanini A, Brandi ML. Osteodifferentiation of human preadipocytes induced by strontium released from hydrogels. *Int J Biomater* 2012; **2012**: 865291 [PMID: 22927856 DOI: 10.1155/2012/865291]

77 **Zhou C**, Shi Q, Guo W, Terrell L, Qureshi AT, Hayes DJ, Wu Q. Electrospun bio-nanocomposite scaffolds for bone tissue engineering by cellulose nanocrystals reinforcing maleic anhydride grafted PLA. *ACS Appl Mater Interfaces* 2013; **5**: 3847-3854 [PMID: 23590943 DOI: 10.1021/am4005072]

78 **Kishimoto S**, Ishihara M, Mori Y, Takikawa M, Sumi Y, Nakamura S, Sato T, Kiyosawa T. Three-dimensional expansion using plasma-medium gel with fragmin/protamine nanoparticles and fgf-2 to stimulate adipose-derived stromal cells and bone marrow-derived mesenchymal stem cells. *Biores Open Access* 2012; **1**: 314-323 [PMID: 23514899 DOI: 10.1089/biores.2012.0251]

79 **Correia C**, Bhumiratana S, Yan LP, Oliveira AL, Gimble JM, Rockwood D, Kaplan DL, Sousa RA, Reis RL, Vunjak-Novakovic G. Development of silk-based scaffolds for tissue engineering of bone from human adipose-derived stem cells. *Acta Biomater* 2012; **8**: 2483-2492 [PMID: 22421311 DOI: 10.1016/j.actbio.2012.03.019]

80 **Fan J**, Park H, Tan S, Lee M. Enhanced osteogenesis of adipose derived stem cells with Noggin suppression and delivery of BMP-2. *PLoS One* 2013; **8**: e72474 [PMID: 23977305 DOI: 10.1371/journal.pone.0072474]

81 **Haimi S**, Gorianc G, Moimas L, Lindroos B, Huhtala H, Räty S, Kuokkanen H, Sándor GK, Schmid C, Miettinen S, Suuronen R. Characterization of zinc-releasing three-dimensional bioactive glass scaffolds and their effect on human adipose stem cell proliferation and osteogenic differentiation. *Acta Biomater* 2009; **5**: 3122-3131 [PMID: 19428318 DOI: 10.1016/j.actbio.2009.04.006]

82 **Leong DT**, Nah WK, Gupta A, Hutmacher DW, Woodruff MA. The osteogenic differentiation of adipose tissue-derived precursor cells in a 3D scaffold/matrix environment. *Curr Drug Discov Technol* 2008; **5**: 319-327 [PMID: 19075612 DOI: 10.2174/157016308786733537]

83 **McCullen SD**, Zhu Y, Bernacki SH, Narayan RJ, Pourdeyhimi B, Gorga RE, Loboa EG. Electrospun composite poly(L-lactic acid)/tricalcium phosphate scaffolds induce proliferation and osteogenic differentiation of human adipose-derived stem cells. *Biomed Mater* 2009; **4**: 035002 [PMID: 19390143 DOI: 10.1088/1748-6041/4/3/035002]

84 **Asli MM**, Pourdeyhimi B, Loboa EG. Release profiles of tricalcium phosphate nanoparticles from poly(L-lactic acid) electrospun scaffolds with single component, core-sheath, or porous fiber morphologies: effects on hASC viability and osteogenic differentiation. *Macromol Biosci* 2012; **12**: 893-900 [PMID: 22648935 DOI: 10.1002/mabi.201100470]

85 **Müller AM**, Davenport M, Verrier S, Droeser R, Alini M, Bocelli-Tyndall C, Schaefer DJ, Martin I, Scherberich A. Platelet lysate as a serum substitute for 2D static and 3D perfusion culture of stromal vascular fraction cells from human adipose tissue. *Tissue Eng Part A* 2009; **15**: 869-875 [PMID: 19191518 DOI: 10.1089/ten.tea.2008.0498]

86 **Reddy S**, Wasnik S, Guha A, Kumar JM, Sinha A, Singh S. Evaluation of nano-biphasic calcium phosphate ceramics for bone tissue engineering applications: in vitro and preliminary in vivo studies. *J Biomater Appl* 2013; **27**: 565-575 [PMID: 22286210 DOI: 10.1177/0885328211415132]

87 **Haslauer CM**, Moghe AK, Osborne JA, Gupta BS, Loboa EG. Collagen-PCL sheath-core bicomponent electrospun scaffolds increase osteogenic differentiation and calcium accretion of human adipose-derived stem cells. *J Biomater Sci Polym Ed* 2011; **22**: 1695-1712 [PMID: 20836922 DOI: 10.1163/092050610X521595]

88 **Ahn HH**, Kim KS, Lee JH, Lee JY, Kim BS, Lee IW, Chun HJ, Kim JH, Lee HB, Kim MS. In vivo osteogenic differentiation of human adipose-derived stem cells in an injectable in situ-forming gel scaffold. *Tissue Eng Part A* 2009; **15**: 1821-1832 [PMID: 19132893 DOI: 10.1089/ten.tea.2008.0386]

89 **Güven S**, Mehrkens A, Saxer F, Schaefer DJ, Martinetti R, Martin I, Scherberich A. Engineering of large osteogenic grafts with rapid engraftment capacity using mesenchymal and endothelial progenitors from human adipose tissue. *Biomaterials* 2011; **32**: 5801-5809 [PMID: 21605897 DOI: 10.1016/j.biomaterials.2011.04.064]

90 **Papadimitropoulos A**, Scherberich A, Güven S, Theilgaard N, Crooijmans HJ, Santini F, Scheffler K, Zallone A, Martin I. A 3D in vitro bone organ model using human progenitor cells. *Eur Cell Mater* 2011; **21**: 445-58; discussion 458 [PMID: 21604244]

91 **Leong DT**, Abraham MC, Rath SN, Lim TC, Chew FT, Hutmacher DW. Investigating the effects of preinduction on human adipose-derived precursor cells in an athymic rat model. *Differentiation* 2006; **74**: 519-529 [PMID: 17177849 DOI: 10.1111/j.1432-0436.2006.00092.x]

92 **Conejero JA**, Lee JA, Parrett BM, Terry M, Wear-Maggitti K, Grant RT, Breitbart AS. Repair of palatal bone defects using osteogenically differentiated fat-derived stem cells. *Plast Reconstr Surg* 2006; **117**: 857-863 [PMID: 16525276 DOI: 10.1097/01.prs.0000204566.13979.c1]

93 **Choi HJ**, Kim JM, Kwon E, Che JH, Lee JI, Cho SR, Kang SK, Ra JC, Kang BC. Establishment of efficacy and safety assessment of human adipose tissue-derived mesenchymal stem cells (hATMSCs) in a nude rat femoral segmental defect model. *J Korean Med Sci* 2011; **26**: 482-491 [PMID: 21468254 DOI: 10.3346/jkms.2011.26.4.482]

94 **Levi B**, James AW, Nelson ER, Vistnes D, Wu B, Lee M, Gupta A, Longaker MT. Human adipose derived stromal cells heal critical size mouse calvarial defects. *PLoS One* 2010; **5**: e11177 [PMID: 20567510 DOI: 10.1371/journal.pone.0011177]

95 **Pieri F**, Lucarelli E, Corinaldesi G, Aldini NN, Fini M, Parrilli A, Dozza B, Donati D, Marchetti C. Dose-dependent effect of adipose-derived adult stem cells on vertical bone regeneration in rabbit calvarium. *Biomaterials* 2010; **31**: 3527-3535 [PMID: 20170950 DOI: 10.1016/j.biomaterials.2010.01.066]

96 **Keibl C**, Fügl A, Zanoni G, Tangl S, Wolbank S, Redl H, van Griensven M. Human adipose derived stem cells reduce callus volume upon BMP-2 administration in bone regeneration. *Injury* 2011; **42**: 814-820 [PMID: 21457972 DOI: 10.1016/j.injury.2011.03.007]

97 **Li X**, Liu H, Niu X, Yu B, Fan Y, Feng Q, Cui FZ, Watari F. The use of carbon nanotubes to induce osteogenic differentiation of human adipose-derived MSCs in vitro and ectopic bone formation in vivo. *Biomaterials* 2012; **33**: 4818-4827 [PMID: 22483242 DOI: 10.1016/j.biomaterials.2012.03.045]

98 **Lendeckel S**, Jödicke A, Christophis P, Heidinger K, Wolff J, Fraser JK, Hedrick MH, Berthold L, Howaldt HP. Autologous stem cells (adipose) and fibrin glue used to treat widespread traumatic calvarial defects: case report. *J Craniomaxillofac Surg* 2004; **32**: 370-373 [PMID: 15555520 DOI: 10.1016/j.jcms.2004.06.002]

99 **Mesimäki K**, Lindroos B, Törnwall J, Mauno J, Lindqvist C, Kontio R, Miettinen S, Suuronen R. Novel maxillary reconstruction with ectopic bone formation by GMP adipose stem cells. *Int J Oral Maxillofac Surg* 2009; **38**: 201-209 [PMID: 19168327 DOI: 10.1016/j.ijom.2009.01.001]

100 **Sándor GK**, Tuovinen VJ, Wolff J, Patrikoski M, Jokinen J, Nieminen E, Mannerström B, Lappalainen OP, Seppänen R, Miettinen S. Adipose stem cell tissue-engineered construct used to treat large anterior mandibular defect: a case report and review of the clinical application of good manufacturing practice-level adipose stem cells for bone regeneration. *J Oral Maxillofac Surg* 2013; **71**: 938-950 [PMID: 23375899 DOI: 10.1016/j.joms.2012.11.014]

101 **Kulakov AA**, Goldshtein DV, Grigoryan AS, Rzhaninova AA, Alekseeva IS, Arutyunyan IV, Volkov AV. Clinical study of the efficiency of combined cell transplant on the basis of multipotent mesenchymal stromal adipose tissue cells in patients with pronounced deficit of the maxillary and mandibulary bone tissue. *Bull Exp Biol Med* 2008; **146**: 522-525 [PMID: 19489333 DOI: 10.1007/s10517-009-0322-8]

102 **Mao JJ**, Giannobile WV, Helms JA, Hollister SJ, Krebsbach PH, Longaker MT, Shi S. Craniofacial tissue engineering by stem cells. *J Dent Res* 2006; **85**: 966-979 [PMID: 17062735 DOI: 10.1177/154405910608501101]

103 **Sándor GK**. Tissue engineering of bone: Clinical observations with adipose-derived stem cells, resorbable scaffolds, and growth factors. *Ann Maxillofac Surg* 2012; **2**: 8-11 [PMID: 23483030 DOI: 10.4103/2231-0746.95308]

**P-Reviewers:** Jun Y, Liu L, Maraldi T **S-Editor:** Ma YJ **L-Editor:** **E-Editor:**

**Table 1 Summary of current representative bone tissue engineering models combined with human**

**adipose-derived stem/stromal cells**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Scaffold Origin** | **Type of Scaffold** | **Active Molecule** | **Study Type** | **Differentiation Pre-Implant** | **Implant Area** | **Species** | **Reference** |
| Synthetic | BCP | - | *In vitro* | Yes | - | - | 73 |
| Synthetic | Ti6Al4V | - | *In vitro* | Yes | - | - | 74 |
| Synthetic | Ti6Al4V | - | *In vitro* | Yes | - | - | 75 |
| Semi-synthetic | CMCA | Sr2+ | *In vitro* | Yes | - | - | 76 |
| Semi-synthetic | MPLA/CNC | - | *In vitro* | - | - | - | 77 |
| Semi-synthetic | Silk/Fibroin | - | *In vitro* | Yes | - | - | 79 |
| Semi-synthetic | Apatite-coated CH/CS | rhBMP-2 | *In vitro* | Yes | - | - | 80 |
| Synthetic | Bioactive glass | - | *In vitro* | Yes | - | - | 81 |
| Synthetic | PCL | - | *In vitro* | Yes | - | - | 82 |
| Synthetic | PLA/β-TCP | - | *In vitro* | Yes | - | - | 83 |
| Synthetic | PLA/β-TCP | - | *In vitro* | Yes | - | - | 84 |
| Synthetic | BCP | - | *In vitro/In vivo* | Yes | Femur | Rat | 86 |
| Semi-synthetic | Collagen/PCL | - | *In vitro* | Yes | - | - | 87 |
| Synthetic | PEG/PCL | - | *In vitro/In vivo* | - | Subcutaneous | Rat | 88 |
| Synthetic | HA | - | *In vitro/In vivo* | - | Subcutaneous | Rat | 89 |
| Synthetic | HA/ β-TCP | - | *In vitro/In vivo* | - | Subcutaneous | Mouse | 90 |
| Synthetic | PCL/β-TCP | - | *In vivo* | - | Subcutaneous | Rat | 91 |
| Synthetic | PLA | - | *In vivo* | Yes | Palate | Rat | 92 |
| Synthetic | HA/β-TCP | - | *In vivo* | - | Femur | Rat | 93 |
| Synthetic | Apatite-coated PLGA | rhBMP-2 | *In vivo* | - | Calvaria | Mouse | 94 |
| Semi-synthetic | ABB/Titanium | - | *In vivo* | - | Calvaria | Rabbit | 95 |
| Natural | Fibrin matrix | BMP-2 | *In vivo* | - | Femur | Rat | 96 |
| Synthetic | Carbon nanotube | rhBMP-2 | *In vitro/In vivo* | Yes | Subcutaneous | Mouse | 97 |
| Natural | Fibrin glue | - | *In vivo* | - | Calvaria | Human | 98 |
| Synthetic | β-TCP/Titanium | rhBMP-2 | *In vivo* | - | Maxilla | Human | 99 |
| Synthetic | β-TCP | rhBMP-2 | *In vivo* | Yes | Mandibula | Human | 100 |
| Natural | ABB | PRP | *In vivo* | Yes | Maxilla/Mandibula | Human | 101 |
| Synthetic | β-TCP/bioactive glass | rhBMP-2 | *In vivo* | Yes | Craniofacial | Human | 103 |

BCP: Biphasic calcium phosphate ceramics; Ti6Al4V: Titanium alloy; CMCA: Amidate carboxymethilcellulose; PLA: Poly(L-lactic acid); MPLA/CNC: Maleic anhydride grafted PLA/cellulose nanocrystals; CH/CS: Chitosan/chondroitin sulfate; PCL: Polycaprolactone; β-TCP: β-tricalcium phosphate; PEG: Polyethylene glycol; HA: Hydroxyapatite; PLGA: Poly(L-lactic acid-co-glycolic acid); ABB: Anorganic bovine bone; Sr2+: Strontium ion; rhBMP-2: Recombinant human bone morphogenetic protein; PRP: Platelet-rich plasma.